Testosterone Use Not Tied to Gynecological Cancers in Transmasculine Individuals
By Lori Solomon HealthDay Reporter
FRIDAY, May 16, 2025 -- Short-term testosterone use among transmasculine and gender diverse (TMGD) individuals is not associated with an increased risk for gynecological cancers, according to a study published online May 12 in eClinicalMedicine.
Asra Vestering, M.D., from the Amsterdam University Medical Center, and colleagues evaluated the incidence of gynecological (pre-)malignancies among 1,955 TMGD individuals using testosterone treatment between Feb. 17, 1972, and Dec. 3, 2018.
The researchers found a median duration of testosterone usage of 1.7 years before hysterectomy and oophorectomy (median age, 24 years) and 3.1 years before vaginal and/or vulvar surgery or biopsy (median age, 29 years). No gynecological malignancies were seen, while expected incidence was ≤0.26 for all cancer types. Across samples, one ovarian borderline tumor, one case of simple endometrial hyperplasia, and one case of vulvar intraepithelial neoplasia (VIN) III were detected. The age-adjusted standardized incidence ratio for >VIN2 was 0.23.
"We found no increased risk of these cancers compared to women from the general population. None of these cancers were diagnosed in the entire participant group," Vestering said in a press release. "This is valuable information for both health care providers and transmasculine and gender-diverse people who are considering starting hormone therapy."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Race Definitions Have Limited Impact on Cancer Rates in Whites, Blacks, Asians
MONDAY, July 21, 2025 -- Race definitions have limited impact on cancer rates for Whites, Blacks, and Asians, but do impact rates in multiracial individuals, according to a study...
Updated Guidance Improves Staging of HPV-Positive Oropharyngeal Cancer
MONDAY, July 21, 2025 -- Version nine of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control staging system (AJCC9V) human papillomavirus...
ENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer Deaths
MONDAY, July 14, 2025 -- From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.